Monoclonal antibodies (mAbs) are a well-established product class of biotechnology-derived pharmaceuticals for treating multiple diseases. A growing number of mAbs are being tested in clinical trials worldwide. Many of the second generation mAbs entering the clinic today are highly engineered, produced from recombinant cell lines, and present new safety challenges for regulators and industry scientists responsible for their safety evaluation. The increasing complexity of antibodies and the variety of recombinant production cell systems used for antibody manufacturing require a well thoughtout approach for preclinical safety evaluation of mAbs. The focus of this chapter is to provide the reader with a basic framework for preparing a scientifically sound preclinical package for safety evaluation of therapeutic mAbs. We outline the general considerations for planning a preclincal program and the issues critical for success. We describe the types of preclinical safety studies and the timing for their conduct in relation to clinical trials. We also share some of the lessons learned about toxicity of mAbs from previous antibody development programs. A list of relevant regulatory documents issued by various government agencies and selected references to other useful texts and publications are also provided in the chapter. We believe that applying the principles described in this chapter will improve the quality and relevance of the preclinical safety data generated to support the future development of mAbs therapeutics.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Adams GP and Weiner LM (2005) Monoclonal antibody therapy of cancer. Nat Biotechnol 23:1147-1157
Berger JR (2006a) Natalizumab and progressive multifocal leucoencephalopathy. Ann Rheum Dis 65:iii48-iii53
Berger JR (2006b) Natalizumab. Drugs Today 42:639-655
Berger JR and Koralnik IJ (2005) Progressive multifocal leukoencephalopathy and natalizumabunforeseen consequences. N Engl J Med 353:414-416
Birch JR Racher AJ (2006) Antibody production. Adv Drug Deliv Rev 58:671-85
Byrd JC et al. (1999) Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance. J Clin Oncol 17: 791-795
Carson KL (2005) Flexibility-the guiding principle for antibody manufacturing. Nat Biotechnol 23:1054-1058
Carter PJ (2006) Potent antibody therapeutics by design. Nat Rev Immunol 6:343-357
Chapman K et al. (2007) Preclinical safety testing of monoclonal antibodies: the significance of species relevance. Nat Rev Drug Discov 6:120-6.
Herbst RS and Langer CJ (2002) Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers. Semin Oncol 29:27-36
Hurwitz H et al. (2004) Bevacizumab plus irinotecan fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342
Hoogenboom HR (2005) Selecting and screening recombinant antibody libraries. Nat Biotechnol 23:1105-1116
Kim SJ et al. (2005) Antibody engineering for the development of therapeutic antibodies. Mol Cells 20:17-29
Kimby E (2005) Tolerability and safety of rituximab (MabThera). Cancer Treat Rev 31:456-73
Lonberg N (2005) Human antibodies from transgenic animals. Nat Biotechnol 23:1117-1125
Phan GQ et al. (2003) Cancer regression and autoimmunity induced by cytotoxic T lymphocyteassociated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA 100:8372-8377
Reichert JM et al. (2005) Monoclonal antibody successes in the clinic. Nat Biotechnol 23:1073-1078
Robert F et al. (2001) Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J Clin Oncol 19(13):3234-3243
Roy D and Andrews PA (2004) Nonclinical testing from theory to practice. In: Teicher BA and Andrews PA (eds), Anticancer drug development guide, 2nd edn, Humana Press, Totowa, NJ, pp 287-311
Scott CT (2005) The problem with potency. Nat Biotechnol 23:1037-1039
Siegel EB (2004) The Pre-Pre-IND FDA consultation process for preclinical studies: opportunities for launching a rapid drug or biologic development program. Preclinica 2:171
Sidiropoulos PI and Boumpas DT (2004) Lessons learned from anti-CD40L treatment in systemic lupus erythematosus patients. Lupus 13:391-397
Slamon DJ et al. (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792
Suntharalingam G et al. (2006) Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 355:1018-1028
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2008 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Lynch, C.M., Grewal, I.S. (2008). Preclinical Safety Evaluation of Monoclonal Antibodies. In: Chernajovsky, Y., Nissim, A. (eds) Therapeutic Antibodies. Handbook of Experimental Pharmacology, vol 181. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-73259-4_2
Download citation
DOI: https://doi.org/10.1007/978-3-540-73259-4_2
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-73258-7
Online ISBN: 978-3-540-73259-4
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)